NeuroSense Therapeutics is currently engaged in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for PrimeC, its lead drug candidate for Amyotrophic Lateral Sclerosis (ALS) treatment. The non-binding terms under discussion indicate potential substantial financial benefits, including upfront payments, milestone payments, and royalties.The company expects to receive formal terms from these discussions in Q4 2024. PrimeC, designed as a combination drug targeting multiple mechanisms involved in ALS progression, has demonstrated promising results in clinical trials. However, NeuroSense cautions that there is no guarantee of reaching a definitive agreement or finalizing terms with any of the pharmaceutical companies.

NeuroSense Therapeutics is currently engaged in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for PrimeC, its lead drug candidate for Amyotrophic Lateral Sclerosis (ALS) treatment. The non-binding terms under discussion indicate potential substantial financial benefits, including upfront payments, milestone payments, and royalties.The company expects to receive formal terms from these discussions in Q4 2024. PrimeC, designed as a combination drug targeting multiple mechanisms involved in ALS progression, has demonstrated promising results in clinical trials. However, NeuroSense cautions that there is no guarantee of reaching a definitive agreement or finalizing terms with any of the pharmaceutical companies.